Friedman Billings Downgrades Acorda Therapeutics (ACOR) to Market Perform
Tweet Send to a FriendGet Alerts ACOR Hot Sheet
Price: $32.61 +0.65%
Rating Summary:
4 Buy, 4 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Rating Summary:
4 Buy, 4 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Trade ACOR Now!
Friedman Billings downgrades Acorda Therapeutics (Nasdaq: ACOR) from Outperform to Market Perform, citing current valuation. However, the firm says the company may build a larger sale force or be the target of a takeover depending on an upcoming FDA decision. Price target $32.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage, biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS).
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage, biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS).
You May Also Be Interested In
- UPDATE: JPMorgan Cuts SodaStream (SODA) to Neutral, 'Stock No Longer Cheap'
- Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
- UPDATE: Sterne Agee Downgrades Beazer Homes (BZH) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Friedman, Billings, Ramsey
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
